July 20, 2018
The FDA has formed a new Drug Shortages Task Force that is being charged to delve into why some drug shortages remain a persistent challenge and to look for solutions for addressing the underlying causes for these shortages. Read More
AbbVie has signed patent license agreements with Mylan over Mylan’s proposed biosimilar to AbbVie’s Humira (adalimumab), its top-selling drug with 2017 sales of $18.43 billion. AbbVie has made similar deals with Amgen and Samsung Bioepis for their Humira biosimilars to enter the US in 2023. Read More
The FDA has announced a voluntary recall of several drug products containing the active ingredient, valsartan, which is used to treat high blood pressure and heart failure. Teva Pharmaceutical Industries and two other generic pharmaceutical providers are involved in the recalls. Read More
Dr. Reddy’s Laboratories has announced its intent to appeal a preliminary injunction made by a federal US district court against further sales and commercialization of Dr. Reddy’s buprenorphine and naloxone sublingual film within the US, a drug for treating opioid dependence. Read More
GlaxoSmithKline (GSK) has agreed to sell the rights to its investigational skincare drug, tapinarof, to Dermavant Sciences, the dermatology subsidiary of Roivant Sciences, a Basel, Switzerland globally headquartered biopharmaceutical company, for £250 million ($330 million).     Read More
The FDA has issued draft guidance as part of the agency’s effort to increase access to nonprescription drugs as a means to increase drug competition. The draft guidance is part of a new initiative to establish innovative approaches, including through the use of digital tools, to increase access to a wider selection of nonprescription drug products. Read More
Valeant Pharmaceuticals International has completed the change of its company name to Bausch Health Companies, as previously announced in May 2018. The new name is taken from its subsidiary, Bausch + Lomb, an eye-care company, which Valeant acquired in 2013. Read More
Novartis has signed an agreement with CELLforCURE, a CDMO and part of the biopharmaceutical company, LFB, to produce chimeric antigen receptor T-cell (CAR-T) therapies at CELLforCURE’s bioproduction site in Les Ulis, France. The company says that production could start in 2019. Read More
SK Holdings, a Seoul, South Korea-based holding company of SK Group, has agreed to acquire Ampac Fine Chemicals, a contract manufacturer of active pharmaceutical ingredients (API) and intermediates. This is the second recent acquisition by SK to grow its contract API manufacturing services. Read More
Top Industry News is published and distributed by the Drug, Chemical & Associated Technologies Association (DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit www.dcat.org .